Thursday, June 10, 2021

Alzheimer Drug - - btbirkett@gmail.com - Gmail

The housing market’s fever shows more signs of breaking - btbirkett@gmail.com - Gmail

Our So-Called Health-Care System

Max Nisen wrote earlier this week that the FDA shouldn’t have approved Biogen’s new Alzheimer’s drug, Aduhelm. There’s just no proof the thing works the way it’s supposed to. Biogen has been given infinity years to run more trials, but in the meantime it will sell the drug at $56,000 a year. Side effects of paying $56,000 a year for what could be a fancy Flintstone vitamin may include night terrors, day terrors, wealth hemorrhaging and Sudden Asset Disappearance Syndrome (SADS).  

This episode highlights two specific problems with America’s problem-rich health-care system, writes Bloomberg’s editorial board. First, the FDA is way too willing to let iffy drugs on the market. Second, once those iffy drugs are on the market, Medicare is prohibited by law from scoffing whenever it’s presented with a bill for $56,000 or whatever for them. 

So to recap:

  • Drug maybe doesn’t work.
  • Drug costs $56,000.
  • Taxpayers must eat the cost of drug.

Great system! 

No comments:

Post a Comment